Boston Scientific Buys Vertiflex For $465M To Add Minimally Invasive Lumbar Procedure
Vertiflex sells the Superion indirect decompression system, a minimally invasive device to treat lumbar spinal stenosis. Boston Scientific expects it to bring in $60m in revenue in 2019 to its Neuromodulation business.
You may also be interested in...
The Oxford University spin-off has raised over £3m so far to develop its minimally invasive disc nucleus replacement technology and plans a £10m series A.
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.